Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02030834
Recruitment Status : Active, not recruiting
First Posted : January 9, 2014
Last Update Posted : June 26, 2020
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 16, 2019
Estimated Study Completion Date : July 2021
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 September 9, 2020